These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19072881)

  • 1. B-type natruiretic peptide levels stratify the risk for arrhythmia among implantable cardioverter defibrillator patients.
    Galante O; Amit G; Zahger D; Wagshal A; Ilia R; Katz A
    Clin Cardiol; 2008 Dec; 31(12):586-9. PubMed ID: 19072881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of N-terminal pro-brain natriuretic peptide versus electrophysiologic study for predicting future outcomes in patients with an implantable cardioverter defibrillator after myocardial infarction.
    Yu H; Oswald H; Gardiwal A; Lissel C; Klein G
    Am J Cardiol; 2007 Aug; 100(4):635-9. PubMed ID: 17697820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated B-type natriuretic peptide levels in patients with nonischemic cardiomyopathy predict occurrence of arrhythmic events.
    Simon T; Becker R; Voss F; Bikou O; Hauck M; Licka M; Katus HA; Bauer A
    Clin Res Cardiol; 2008 May; 97(5):306-9. PubMed ID: 18193374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Brain natriuretic peptide (BNP) level predicts long term ventricular arrhythmias in patients with moderate to severe left ventricular dysfunction].
    Galante O; Zahger D; Wagshal A; Katz A; Amit G
    Harefuah; 2012 Jan; 151(1):20-3, 63, 62. PubMed ID: 22670496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function.
    Nagahara D; Nakata T; Hashimoto A; Wakabayashi T; Kyuma M; Noda R; Shimoshige S; Uno K; Tsuchihashi K; Shimamoto K
    J Nucl Med; 2008 Feb; 49(2):225-33. PubMed ID: 18199625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain natriuretic peptide and the risk of ventricular tachyarrhythmias in mildly symptomatic heart failure patients enrolled in MADIT-CRT.
    Medina A; Moss AJ; McNitt S; Zareba W; Wang PJ; Goldenberg I
    Heart Rhythm; 2016 Apr; 13(4):852-9. PubMed ID: 26724489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Chronic Total Coronary Occlusion on Recurrence of Ventricular Arrhythmias in Ischemic Secondary Prevention Implantable Cardioverter-Defibrillator Recipients (VACTO Secondary Study): Insights From Coronary Angiogram and Electrogram Analysis.
    Nombela-Franco L; Iannaccone M; Anguera I; Amat-Santos IJ; Sanchez-Garcia M; Bautista D; Calvelo MN; Di Marco A; Moretti C; Pozzi R; Scaglione M; Cañadas V; Sandin-Fuentes M; Arenal A; Bagur R; Perez-Castellano N; Fernandez-Perez C; Gaita F; Macaya C; Escaned J; Fernández-Lozano I
    JACC Cardiovasc Interv; 2017 May; 10(9):879-888. PubMed ID: 28473110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of sleep-disordered breathing to predict occurrence of appropriate and inappropriate implantable-cardioverter defibrillator therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death.
    Kreuz J; Skowasch D; Horlbeck F; Atzinger C; Schrickel JW; Lorenzen H; Nickenig G; Schwab JO
    Am J Cardiol; 2013 May; 111(9):1319-23. PubMed ID: 23411108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy.
    Gold MR; Ip JH; Costantini O; Poole JE; McNulty S; Mark DB; Lee KL; Bardy GH
    Circulation; 2008 Nov; 118(20):2022-8. PubMed ID: 18955671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Arrhythmia, device interventions and mortality analysis in patients with implanted cardioverter-defibrillator with/without resynchronisation therapy in dilative cardiomyopathy in primary prevention of sudden cardiac death].
    Lelakowski J; Pudło J; Lelakowska-Pieła M; Rydlewska A; Piekarz J; Domaracki D
    Pol Merkur Lekarski; 2016 Apr; 40(238):216-22. PubMed ID: 27137820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-analysis.
    Scott PA; Barry J; Roberts PR; Morgan JM
    Eur J Heart Fail; 2009 Oct; 11(10):958-66. PubMed ID: 19789399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baroreflex sensitivity assessed with the sequence method is associated with ventricular arrhythmias in patients implanted with a defibrillator for the primary prevention of sudden cardiac death.
    Garcia R; Degand B; Fraty M; Le Marcis V; Bidegain N; Laude D; Tavernier M; Le Gal F; Hadjadj S; Saulnier PJ; Ragot S
    Arch Cardiovasc Dis; 2019 Apr; 112(4):270-277. PubMed ID: 30670362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated B-type natriuretic peptide is associated with increased in-hospital mortality or cardiac arrest in patients undergoing implantable cardioverter-defibrillator implantation.
    Wei S; Loyo-Berríos NI; Haigney MC; Cheng H; Pinnow EE; Mitchell KR; Beachy JH; Woodward AM; Wang Y; Curtis JP; Marinac-Dabic D
    Circ Cardiovasc Qual Outcomes; 2011 May; 4(3):346-54. PubMed ID: 21487093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias.
    Levine YC; Rosenberg MA; Mittleman M; Samuel M; Methachittiphan N; Link M; Josephson ME; Buxton AE
    Heart Rhythm; 2014 Jul; 11(7):1109-16. PubMed ID: 24837348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-type natriuretic peptide and risk of sudden death in patients with hypertrophic cardiomyopathy.
    Minami Y; Haruki S; Kanbayashi K; Maeda R; Itani R; Hagiwara N
    Heart Rhythm; 2018 Oct; 15(10):1484-1490. PubMed ID: 29709578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amino-terminal pro-brain natriuretic peptide predicts ventricular arrhythmogenesis in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillators.
    Manios EG; Kallergis EM; Kanoupakis EM; Mavrakis HE; Kambouraki DC; Arfanakis DA; Vardas PE
    Chest; 2005 Oct; 128(4):2604-10. PubMed ID: 16236931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of microvolt T-wave alternans testing in scheduling implantable cardioverter-defibrillator placement for the primary prevention of sudden cardiac death in patients with left ventricular dysfunction.
    Daniłowicz-Szymanowicz L; Suchecka J; Zagożdżon P; Szwoch M; Kempa M; Raczak G
    Kardiol Pol; 2015; 73(6):429-36. PubMed ID: 25371309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arrhythmic burden among asymptomatic patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator.
    Sabbag A; Glikson M; Suleiman M; Boulos M; Goldenberg I; Beinart R; Nof E
    Heart Rhythm; 2019 Jun; 16(6):813-819. PubMed ID: 31153454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of gamma-glutamyltransferase for ventricular arrhythmias and cardiovascular mortality in implantable cardioverter-defibrillator patients.
    Zhou Y; Zhao S; Chen K; Hua W; Zhang S
    BMC Cardiovasc Disord; 2019 May; 19(1):129. PubMed ID: 31146684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
    Yazaki K; Suzuki A; Shiga T; Minami Y; Arai K; Ashihara K; Shoda M; Hagiwara N
    BMC Cardiovasc Disord; 2021 Feb; 21(1):106. PubMed ID: 33607967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.